REZULIN
Rezulin was developed by Parke Davis, a division of Warner Lambert,
to help facilitate insulin absorption for patients with Type If Diabetes.
By 1999, the Los Angeles Times reported 55 deaths prior to the July 1998
labeling change and 57 deaths after July 1998. In March 21, 2000, Rezulin
was voluntarily removed from the U.S. market but only after two million
prescriptions and $1.8 billion in sales.
Serious
Adverse Effects can include:
Elevated Liver Enzymes Jaundice
Liver Failure
Left Ventricular Hypertrophy
|
|